Revista Colombiana de Cancerologia is a premier journal dedicated to advancing the field of oncology in Colombia and beyond. Published by the Instituto Nacional de Cancerología, this journal serves as a vital platform for the dissemination of high-quality research, comprehensive reviews, and innovative methodologies pertinent to cancer research and treatment. With an ISSN of 0123-9015 and E-ISSN 2346-0199, it aims to engage a diverse audience, including researchers, healthcare professionals, and students, fostering collaboration and knowledge sharing within the oncology community. Although specific metrics such as impact factors and H-index are currently unavailable, the journal is committed to maintaining high academic standards and encouraging open access to vital oncological insights. The Revista Colombiana de Cancerologia is positioned as an essential resource for those interested in the latest advancements in cancer care, prevention, and research methodologies, making significant contributions to the understanding and management of cancer.

ORAL ONCOLOGY is a leading peer-reviewed journal published by Elsevier, dedicated to advancing the field of oncology with a specific focus on oral diseases and cancers. Since its inception in 1996, this esteemed journal has provided a platform for high-quality research that addresses critical issues in oral surgery, cancer research, and related disciplines. With impressive rankings in Q1 in Oncology and Q1 in Oral Surgery, and recognized as Rank #1 in Dentistry and Oral Surgery by Scopus, ORAL ONCOLOGY consistently publishes impactful articles that contribute significantly to our understanding of oral cancers. The journal is committed to sharing pioneering findings that enhance clinical practices and improve patient outcomes. As a non-open access journal, it provides readers with exclusive access to cutting-edge research, ensuring that professionals, researchers, and students are at the forefront of developments in the field. Situated in the United Kingdom, ORAL ONCOLOGY serves as an indispensable resource for those dedicated to advancing oral health and oncology research through rigorous scientific inquiry and collaboration.

Ceska Gynekologie-Czech Gynaecology, ISSN 1210-7832, is a prominent journal in the field of obstetrics and gynecology, published by the esteemed NAKLADATELSKE STREDISKO C L S J E PURKYNE in the Czech Republic. Since its inception in 1959, this journal has served as a vital resource for researchers, practitioners, and students by disseminating high-quality research and insights pertinent to women's health. The journal is currently ranked in the Q3 category for Obstetrics and Gynecology, reflecting its respected position within the academic community, despite its Scopus ranking of #161 out of 209 in the medical field. Ceska Gynekologie offers a platform for sharing innovative clinical practices, research advancements, and educational resources, contributing significantly to the advancement of gynecological care. With a commitment to fostering professional knowledge and practice, this journal remains an essential tool for those engaged in the intricate world of women's health.

Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.

Welcome to the International Journal of Biological Markers, a distinguished publication under SAGE Publications Ltd that has been a vital resource in the fields of Cancer Research, Clinical Biochemistry, Oncology, and Pathology and Forensic Medicine since its inception in 1986. With a commitment to disseminating high-quality research, the journal enjoys a robust impact highlighted by its Q2 and Q3 rankings across multiple categories in 2023, as evidenced by its Scopus rankings placing it in respectable percentiles. Based in Italy, this journal serves a global audience of researchers, clinicians, and students eager to keep abreast of the latest discoveries involving biological markers and their applications in medicine. Emphasizing rigorous peer review and scholarly integrity, the International Journal of Biological Markers plays a crucial role in advancing knowledge that can significantly impact clinical practices and enhance patient care.

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

Journal of Thoracic Oncology, published by Elsevier Science Inc, is a premier scholarly outlet dedicated to advancing the field of thoracic oncology. With an impressive impact factor and consistently rated in the Q1 quartile across several pertinent categories such as Medicine, Oncology, and Pulmonary and Respiratory Medicine, this journal stands at the forefront of research dissemination. Covering a broad scope that includes innovative therapeutic approaches, clinical trials, and the molecular underpinnings of thoracic malignancies, the journal serves as a vital resource for researchers, healthcare professionals, and students seeking to enhance their understanding of thoracic cancer and its treatment. With publication dates converging from 2006 to 2024, the Journal of Thoracic Oncology fosters a collaborative scholarly community by providing a platform for high-quality research while ensuring accessibility through traditional publication formats. Positioned in the heart of New York City, this journal not only reflects the cutting-edge advancements in oncology but also plays a pivotal role in shaping the future of thoracic cancer care.

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

Case Reports in Oncological Medicine is a distinguished open-access journal published by HINDAWI LTD, dedicated to disseminating valuable insights and findings in the field of oncology. Since its inception in 2011, this journal has aimed to provide a unique platform for the publication of detailed case reports that contribute to our understanding of cancer diagnosis, treatment, and management. With a specific focus on sharing clinical experiences and outcomes, it seeks to engage researchers, healthcare professionals, and students who are committed to advancing oncological knowledge and improving patient care. Although coverage in Scopus was discontinued from 2014 to 2017, the journal currently holds a rank of #232/323 in Medicine - Oncology, placing it within the 28th percentile. Researchers interested in making their work accessible can benefit from the journal's open-access model, allowing greater visibility and citation potential within the scientific community. The journal is positioned as an important resource for those looking to stay updated on the latest case studies and innovations in oncological medicine.

BMC CANCER is a prestigious, peer-reviewed journal dedicated to advancing the field of cancer research and oncology since its inception in 2001. Published by BMC, a leading name in open-access publishing, this journal plays a crucial role in providing researchers, professionals, and students with a platform for high-quality scientific discourse. With an impressive impact factor, BMC CANCER is ranked in the Q2 quartile across multiple categories, including Cancer Research, Genetics, and Oncology, reflecting its commitment to impactful research and rigorous peer-review standards. The journal ensures broad accessibility to its content through its Open Access model, allowing findings to reach a global audience without financial barriers. The editorial board consists of recognized experts committed to fostering innovation and collaboration within the cancer research community. Researchers working at the intersection of cancer biology, treatment options, and genetic influences will find BMC CANCER an invaluable resource for sharing their findings and engaging with the latest developments in the field.